QIAGEN N.V. $QGEN Stock Position Reduced by HighTower Advisors LLC

Key Points

• HighTower Advisors LLC reduced its stake in Qiagen N.V. by 43% in the first quarter, now holding 10,333 shares valued at $415,000 after selling 7,805 shares.
• Deutsche Bank AG increased its holdings in Qiagen by 57.5%, now owning 4,491,131 shares worth approximately $180.3 million.
• Qiagen reported a revenue increase of 7.7% year-over-year, with EPS meeting expectations at $0.60 per share for the last quarter.

HighTower Advisors LLC reduced its stake in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) by 43.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,333 shares of the company's stock after selling 7,805 shares during the period. HighTower Advisors LLC's holdings in QIAGEN were worth $415,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in QGEN. Exchange Traded Concepts LLC raised its holdings in shares of QIAGEN by 2.3% in the 1st quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock worth $716,000 after purchasing an additional 395 shares in the last quarter. Cetera Investment Advisers raised its holdings in shares of QIAGEN by 14.4% in the 4th quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock worth $505,000 after purchasing an additional 1,418 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of QIAGEN by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after purchasing an additional 1,425 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of QIAGEN by 770.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock worth $111,000 after purchasing an additional 2,204 shares in the last quarter. Finally, Avantax Advisory Services Inc. raised its holdings in shares of QIAGEN by 30.2% in the 1st quarter. Avantax Advisory Services Inc. now owns 9,869 shares of the company's stock worth $396,000 after purchasing an additional 2,290 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

QGEN has been the topic of a number of research reports. Barclays initiated coverage on shares of QIAGEN in a report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price on the stock. Cowen reiterated a "hold" rating on shares of QIAGEN in a report on Thursday, August 7th. Wall Street Zen downgraded shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. UBS Group boosted their target price on shares of QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Finally, Bank of America lifted their target price on shares of QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $49.69.

QIAGEN Trading Up 1.1%

Shares of QIAGEN stock traded up $0.50 during trading on Friday, hitting $47.54. The stock had a trading volume of 939,634 shares, compared to its average volume of 1,350,406. The stock has a 50 day simple moving average of $48.65 and a 200 day simple moving average of $44.35. The company has a market capitalization of $10.57 billion, a PE ratio of 28.08, a P/E/G ratio of 2.48 and a beta of 0.64. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. QIAGEN N.V. has a 1 year low of $37.63 and a 1 year high of $51.88.

QIAGEN (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting analysts' consensus estimates of $0.60. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The firm had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. During the same period in the previous year, the firm posted $0.55 earnings per share. The firm's revenue was up 7.7% on a year-over-year basis. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, research analysts expect that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.